Ototoxicity from ototopical aminoglycosides.
Hui
Y
Y
Department of Otolaryngology, Hospital for Sick Children, Toronto, Ontario.
Park
A
A
Crysdale
W S
WS
Forte
V
V
D000287:Administration, Topical; D000293:Adolescent; D000900:Anti-Bacterial Agents / Q000009:adverse effects* / Q000627:therapeutic use; D000893:Anti-Inflammatory Agents / Q000009:adverse effects / Q000627:therapeutic use; D001301:Audiometry, Pure-Tone; D003907:Dexamethasone / Q000009:adverse effects / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005601:Framycetin / Q000009:adverse effects / Q000627:therapeutic use; D005839:Gentamicins / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D006096:Gramicidin / Q000009:adverse effects / Q000627:therapeutic use; D006314:Hearing Loss, Conductive / Q000175:diagnosis / Q000209:etiology; D006801:Humans; D008297:Male; D010034:Otitis Media with Effusion / Q000150:complications / Q000188:drug therapy*; D018058:Tympanic Membrane Perforation / Q000209:etiology
D000900:Anti-Bacterial Agents; D000893:Anti-Inflammatory Agents; D005839:Gentamicins; D006096:Gramicidin; D005601:Framycetin; D003907:Dexamethasone